The stock debuted at Rs 120.75, marking a premium of 5.92% to the issue price.

So far, the stock has hit a high of 123.25 and a low of 114. On the BSE, over 11.13 lakh shares of the company were traded in the counter so far.

Gujarat Kidney and Super Speciality was subscribed 5.21 times. The issue opened for bidding on 22 December 2025, and it closed on 24 December 2025. The price band of the IPO was fixed between Rs 108 and 114 per share.

The IPO comprised a fresh issue of equity shares, aggregating up to Rs 250.8 crore. Proceeds are proposed to be used for the acquisition of Parekh’s Hospital in Ahmedabad, part-payment for Ashwini Medical Centre, increasing the stake in subsidiary Harmony Medicare in Bharuch, funding capital expenditure, purchasing robotics equipment for its Vadodara hospital, repayment or prepayment of borrowings, and general corporate purposes.

Ahead of the IPO of Gujarat Kidney and Super Speciality on 22 December 2025, the company raised Rs 100.01 crore from anchor investors by allotting 87.73 lakh shares at Rs 114 each to 10 anchor investors. The promoter held 99.1% of the pre-issue equity share capital, with post-shareholding expected to decline to about 71.45%.

Gujarat Kidney & Super Speciality operates multispecialty hospitals and four pharmacies across Gujarat, with a total bed capacity of 490 beds. For the three months ended 30 June 2025, the firm reported a consolidated net profit of Rs 4.84 crore and income from operations of Rs 15.26 crore.